Scarica l'app Stockscreener
16.78
0.12%
-0.02
Dopo l'orario di chiusura:
16.90
0.12
+0.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BAX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$16.80
Aprire:
$17
Volume 24 ore:
8.41M
Relative Volume:
0.85
Capitalizzazione di mercato:
$8.66B
Reddito:
$11.24B
Utile/perdita netta:
$-900.00M
Rapporto P/E:
-9.994
EPS:
-1.679
Flusso di cassa netto:
$323.00M
1 W Prestazione:
-1.99%
1M Prestazione:
-17.62%
6M Prestazione:
-28.17%
1 anno Prestazione:
-50.68%
Intervallo 1D:
$16.76
$17.20
Intervallo di 1 settimana:
$15.73
$17.50
Portata 52W:
$15.73
$33.83
Baxter International Inc Stock (BAX) Company Profile
Nome
Baxter International Inc
Settore
Industria
Telefono
(224) 948-2000
Indirizzo
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
16.78 | 8.67B | 11.24B | -900.00M | 323.00M | -1.679 |
ISRG
Intuitive Surgical Inc
|
464.45 | 163.73B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
156.34 | 44.73B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.51 | 36.73B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.00 | 36.12B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
222.85 | 32.70B | 5.40B | 1.49B | 1.78B | 10.12 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Downgrade | Argus | Buy → Hold |
| 2025-08-04 | Downgrade | Stifel | Buy → Hold |
| 2025-08-01 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-26 | Ripresa | Goldman | Buy |
| 2025-02-24 | Aggiornamento | Argus | Hold → Buy |
| 2025-02-20 | Ripresa | Barclays | Overweight |
| 2024-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-06-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-18 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-18 | Reiterato | Raymond James | Outperform |
| 2022-02-18 | Reiterato | Stifel | Buy |
| 2022-02-18 | Reiterato | UBS | Neutral |
| 2022-02-18 | Reiterato | Wells Fargo | Overweight |
| 2022-02-11 | Iniziato | Goldman | Neutral |
| 2022-01-07 | Ripresa | Citigroup | Buy |
| 2022-01-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-09-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Downgrade | UBS | Buy → Neutral |
| 2020-12-15 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-09-04 | Downgrade | Argus | Buy → Hold |
| 2020-06-24 | Iniziato | Oppenheimer | Outperform |
| 2020-03-19 | Aggiornamento | Stifel | Hold → Buy |
| 2020-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-01-02 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Aggiornamento | Argus | Hold → Buy |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-05-17 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-06 | Reiterato | Citigroup | Neutral |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
Mostra tutto
Baxter International Inc Borsa (BAX) Ultime notizie
Columbia Intrinsic Value Fund's Baxter International Inc(BAX) Holding History - GuruFocus
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International Introduces IV Verify to Improve the Precision of IV Labeling - bitget.com
Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy - Yahoo Finance
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings - BioSpace
Pet Partners, Baxter Foundation Expand Therapy Animal Programs for Patients, Healthcare Workers - Pet Age
Baxter (BAX) Unveils New IV Verify Line Labeling System for Nurs - GuruFocus
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Baxter International Hits New 52-Week Low at $15.87 - Markets Mojo
Baxter International Inc (BAX) Stock Price Down 4.2% on Mar 30 - GuruFocus
Baxter launches IV labeling system aimed at improving safety, efficiency - Medical Economics
Baxter debuts automated IV line labeling system By Investing.com - in.investing.com
Baxter debuts automated IV line labeling system - Investing.com
Baxter rolls out barcode IV labels aimed at cutting bedside errors - Stock Titan
Baxter stock price forecast: bearish trend persists as BAX trades near 52-week lows - Traders Union
Baxter Foundation Therapy Animal Push And What It Means For Investors - simplywall.st
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter International (NYSE:BAX) Hits New 1-Year LowTime to Sell? - MarketBeat
Baxter International stock hits 52-week low at 16.07 USD By Investing.com - Investing.com Australia
Baxter International stock hits 52-week low at 16.07 USD - Investing.com
BAX SEC FilingsBaxter Intl Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Clinical Nutrition for Cancer Care: 2026-2030 Market - GlobeNewswire
Clinical Nutrition for Cancer Care: 2026-2030 Market Analysis Featuring Profiles of Leading PlayersAbbott Nutrition, Baxter International, B Braun Melsungen, Nestle Health Science, Danone Nutricia and More - Yahoo Finance UK
Bank of America maintains a hold rating on Baxter International (BAX) - MSN
Baxter International Stock: Navigating Leadership Changes and Portfolio Optimization Amid Market Pre - AD HOC NEWS
Bank of America Maintains a Hold Rating on Baxter International (BAX) - Insider Monkey
A Look At Baxter International (BAX) Valuation As CFO Transition Draws Investor Attention - simplywall.st
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
[SCHEDULE 13G/A] BAXTER INTERNATIONAL INC Amended Passive Investment Disclosure - Stock Titan
SG Americas Securities LLC Has $32.97 Million Stock Position in Baxter International Inc. $BAX - marketbeat.com
Baxter to Host Annual Meeting of Stockholders in Virtual Format - marketscreener.com
Baxter investors get online-only annual meeting, with voting on May 5 - stocktitan.net
Baxter International stock faces pressure from ifosfamide shortage and reduced production capacity a - AD HOC NEWS
Manufacturing Disruption Hits Baxter Cancer Drug Supply In Europe - sahmcapital.com
Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot - Finviz
Therapy animals will reach 100,000 patients and care teams in pilot - stocktitan.net
EXCLUSIVE: Petrochemical Crunch From Iran War Isn't Hitting Hospitals Yet—But Analysts Say Costs For Critical Medical Supplies Could Rise Within Weeks - Benzinga
Revenue of Baxter International from 2021 to 2025 - Statista
EU regulator flags Baxter cancer drug shortage until early next year - KELO-AM
Baxter International Stock Hits Day Low of $16.08 Amid Price Pressure - Markets Mojo
Baxter International Inc. stock faces pressure from EU cancer drug shortage warning until early 2027 - AD HOC NEWS
Baxter says production of ifosfamide resumed, but at reduced capacity that does not meet current demand - marketscreener.com
The Bull Case For Baxter International (BAX) Could Change Following CFO Turnover And FTSE Index Removal - simplywall.st
EU regulator warns of shortage in Baxter's cancer treatment until early 2027 - marketscreener.com
Baxter International Opens Weak with 6.19% Gap Down Amid Market Concerns - Markets Mojo
Baxter International Hits New 52-Week Low at $16.08 - Markets Mojo
Baxter International : 2025 Proxy Statement - marketscreener.com
BAXTER INTERNATIONAL INC ($BAX) Former Chair of the Board, President and CEO 2025 Pay Revealed - Quiver Quantitative
Baxter International's GC Earned $3.8M In 2025 - law360.com
Baxter International Inc stock faces renewed pressure amid kidney care challenges and acquisition in - AD HOC NEWS
Baxter (NYSE: BAX) sets 2026 votes on pay, board size and incentive plan - Stock Titan
Baxter International Inc Azioni (BAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):